Education
About Us
Working with TipRanks
Follow Us
Bioxyne Limited (AU:BXN)
ASX:BXN
BXN Stock Chart & Stats
AU$0.04
<AU$0.01(4.17%)
At close: 4:00 PM EST
AU$0.04
<AU$0.01(4.17%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume631.90K
Average Volume (3M)4.35M
Market Cap
AU$100.80M
Enterprise ValueAU$94.66M
Total Cash (Recent Filing)AU$7.67M
Total Debt (Recent Filing)AU$1.53M
Price to Earnings (P/E)19.2
Beta1.48
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,239,909,200
10 Day Avg. Volume2,483,521
30 Day Avg. Volume4,348,514
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)7.54
Price to Sales (P/S)2.90
P/FCF Ratio22.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA 77% top-line increase reflects substantial demand expansion in regulated medical and B2B channels. Durable revenue momentum supports scale advantages, reinvestment in product development and distribution, and provides a multi-month runway for margin and cash generation improvements if sustained.
Material Free Cash Flow TurnaroundA dramatic FCF recovery (3473.2%) and solid operating-cash-to-net-income and FCF-to-net-income ratios show the business now converts earnings to cash. Improved cash generation increases financial resilience, funds growth capex, and reduces reliance on external financing over the medium term.
Conservative Leverage With High ROEVery low leverage combined with a high ROE indicates effective use of equity and strong financial flexibility. This capital structure supports investment, withstands shocks, and allows strategic spending or partnerships without materially increasing financial risk over the coming quarters.
Bears Say
Relatively Low Gross MarginA 34.3% gross margin constrains the buffer to cover SG&A and absorb pricing or input-cost pressure. Unless production efficiency or procurement improves, margin structure may limit long-term operating leverage and make profitability vulnerable to commodity or regulatory cost shifts over the next several quarters.
Concentration In Regulated Medicinal CannabisHeavy exposure to the regulated cannabis sector creates structural regulatory and market risks: licensing, reimbursement, and policy changes can materially alter addressable markets. This concentration can amplify earnings volatility and complicate multi-quarter planning and market access.
Small Operational Scale And HeadcountA very small team limits operational bandwidth for scaling manufacturing, distribution and regulatory compliance. Execution risk, single-point dependencies and slower roll-out of new products are structural constraints that can curb growth and raise per-unit costs until scale is achieved.
Bioxyne Limited News
BXN FAQ
What was Bioxyne Limited’s price range in the past 12 months?
Bioxyne Limited lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Bioxyne Limited’s market cap?
Bioxyne Limited’s market cap is AU$100.80M.
When is Bioxyne Limited’s upcoming earnings report date?
Bioxyne Limited’s upcoming earnings report date is Feb 26, 2026 which is in 3 days.
How were Bioxyne Limited’s earnings last quarter?
Bioxyne Limited released its earnings results on Aug 29, 2025. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.001.
Is Bioxyne Limited overvalued?
According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued.
Does Bioxyne Limited pay dividends?
Bioxyne Limited does not currently pay dividends.
What is Bioxyne Limited’s EPS estimate?
Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxyne Limited have?
Bioxyne Limited has 2,239,909,200 shares outstanding.
What happened to Bioxyne Limited’s price movement after its last earnings report?
Bioxyne Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -13.793%.
Which hedge fund is a major shareholder of Bioxyne Limited?
Currently, no hedge funds are holding shares in AU:BXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioxyne Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BXN Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$110.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
61.21%
Trailing 12-Months
Asset Growth
192.29%
Trailing 12-Months
Company Description
Bioxyne Limited
Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
Technical Analysis
Wellnex Life Ltd
―
EVE Health Group Limited
―
Holista Colltech Limited
―
Clover Corporation Limited
―
Maggie Beer Holdings Ltd.
―
Options Prices
Currently, No data available
---